Subject: NIH GUIDE - V21(04) 01/31/92
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Thu, 30 Jan 92 08:04 EST

Hi,
   This should be the final part of the NIH GUide for l/3l/92.
  Please post to the NIH Listserver as:
     NIHGUIDE.920131
Thanks.  Have a super day.
                          Dottie
 ---------------------------- Text of forwarded message -----------------------
 
$$XID NIHGUIDE 19920131 V21N04 P1O1 ************************************
X-comment: RFAs described: OD-92-02, HD-92-08
 
NIH Guide - Vol. 21, No. 4 - January 31, 1992
 
$$INDEX BEGIN *******************************************************
 
                               NOTICES
 
$$INDEX N1 **********************************************************
 
REVISED PHS 398 APPLICATION FORM SOON TO BE AVAILABLE
Public Health Service
INDEX:  PUBLIC HEALTH SERVICE
 
$$INDEX N2 **********************************************************
 
ANNUAL ASSURANCE UPDATE AND REPORT ON ACTIVITIES RELATED TO POSSIBLE
MISCONDUCT IN SCIENCE
Public Health Service
INDEX:  PUBLIC HEALTH SERVICE
 
$$INDEX N3 **********************************************************
 
NCI BRIEFING ON "IMPLEMENTATION GRANTS FOR GENE THERAPY PROGRAM IN
CANCER TREATMENT
National Cancer Institute
INDEX:  CANCER
 
$$INDEX N4 **********************************************************
 
FUNDING STRATEGIES FOR FY 1992
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH
        ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION
 
$$INDEX N5 **********************************************************
 
NATIONAL WORKSHOPS ON THE PROTECTION OF HUMAN SUBJECTS
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH
 
                     NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$INDEX R1 **********************************************************
 
SYNTHESIS AND TESTING OF MALE CONTRACEPTIVE AGENTS (RFP NICHD-CD-92-09)
National Institute of Child Health and Human Development
INDEX:  CHILD HEALTH, HUMAN DEVELOPMENT
 
$$INDEX R2 **********************************************************
 
MICROSTIMULATION OF THE SACRAL SPINAL CORD - MAPPING (RFP NIH-NINDS-92-
14)
National Institute of Neurological Disorders and Stroke
INDEX:  NEUROLOGICAL DISORDERS, STROKE
 
$$INDEX R3 **********************************************************
 
MICROMACHINED STIMULATING ELECTRODES (RFP NIH-NINDS-92-13)
National Institute of Neurological Disorders and Stroke
INDEX:  NEUROLOGICAL DISORDERS, STROKE
 
$$INDEX R4 **********************************************************
 
TREATMENT OF RAYNAUD'S SYNDROME - CLINICAL UNITS (RFP NHLBI-HC-92-03)
National Heart, Lung, and Blood Institute
INDEX:  HEART, LUNG, BLOOD
 
$$INDEX R5 **********************************************************
 
CLINICAL TRIAL OF AN IMPLANTABLE CARDIAC DEFIBRILLATOR (RFP NHLBI-HC-
92-10)
National Heart, Lung, and Blood Institute
INDEX:  HEART, LUNG, BLOOD
 
$$INDEX R6 04/27/92 *************************************************
 
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTION PROJECTS (RFA OD-92-02)
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH
 
$$INDEX R7 05/26/92 *************************************************
 
ORTHOTICS AND PROSTHETICS RESEARCH (RFA HD-92-08)
National Institute of Child Health and Human Development
INDEX:  CHILD HEALTH, HUMAN DEVELOPMENT
 
                                     ERRATUM
 
$$INDEX E1 **********************************************************
 
EVALUATION OF IMMUNE-BASED THERAPIES FOR AIDS USING ANIMAL MODELS
National Institute of Allergy and Infectious Diseases
INDEX:  ALLERGY, INFECTIOUS DISEASES
 
$$INDEX END *********************************************************
 
                                    NOTICES
 
$$N1 BEGIN **********************************************************
 
REVISED PHS 398 APPLICATION FORM SOON TO BE AVAILABLE
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
P.T. 34; K.W. 1014006
 
Public Health Service
 
The newly revised Public Health Service grant application form --
Standard Form PHS 398 -- will be available for shipping to applicants
and applicant organizations early in March 1992.  This revision, dated
9/91 and approved through 6/30/94, replaces the current version that
was revised 10/88 and approved through 3/31/91.  Applicants are to use
the new form starting with:  the May 1, 1992, receipt date for AIDS
applications; the May 10, 1992, receipt date for NRSA Institutional
Training Grant applications; the June 1, 1992, receipt date for
unsolicited research grant and Research Career Development Award (RCDA)
applications; and the June 19, 1992, receipt date for the Academic
Research Enhancement Award applications.  Responses to requests for
applications with receipt dates after May 1, 1992, are to use the new
form.
 
The revised PHS 398 form contains many significant changes and
additions.  Some of the more important changes are:  a modest increase
in the page limitations for the research plan and the introduction to
revised applications; restrictions on appendix materials; an
introductory section that describes the peer review process and
includes contact telephone numbers for the awarding components of the
Public Health Service; the requirement to list all of the personnel,
not just the key personnel, on the abstract page; a detailed discussion
of the various assurance and certification requirements; and an
explanation of the required documentation regarding gender and minority
representation in study populations.
 
To request two or more copies of the PHS 398 (revised 9/91), contact:
 
Administrative Services Office (PHS 398)
Division of Research Grants
National Institutes of Health
Westwood Building, Room 436
Bethesda, MD  20892
 
To request a single copy if the PHS 398 (revised 9/92), contact:
 
Office of Grants Inquiries (PHS 398)
Division of Research Grants
National Institutes of Health
Westwood Building, Room 449
Bethesda, MD  20892
 
To assist delivery, please include a completed mailing label for each
box of 50 applications.
 
INQUIRIES
 
Direct questions regarding the use of the PHS 398 revised (9/91) to the
program contact listed in the Program Announcement or Request for
Applications or for unsolicited applications, on of the contacts listed
in the revised PHS 398.
 
$$N1 END ************************************************************
 
$$N2 BEGIN **********************************************************
 
ANNUAL ASSURANCE UPDATE AND REPORT ON ACTIVITIES RELATED TO POSSIBLE
MISCONDUCT IN SCIENCE
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
P.T. 34; K.W. 1014004, 1014006
 
Public Health Service
 
Effective Date:  January 15, 1992
 
The Public Health Service (PHS) scientific misconduct regulation, 42
CFR 50 Subpart A, "Responsibilities of PHS Awardee and Applicant
Institutions for Dealing With and Reporting Possible Misconduct in
Science," requires each institution to make an annual report to the
Office of Scientific Integrity (OSI) on the handling of allegations,
inquiries and investigations into possible scientific misconduct in
connection with research for which PHS funds have been requested or
received and an annual update of the institutional assurance.
 
The official forms for the 1991 annual report were mailed by the OSI in
October 1991 to the institutional official of each institution that
filed an assurance with OSI for 1990-91.  The completed form should
have been returned to the OSI no later than January 15, 1992.  OSI
staff will review and use the form to update the PHS assurance files.
An updated, active assurance is required for any institution to be
eligible to apply for and/or receive PHS grants, fellowships, and
cooperative agreements for research during calendar year 1992.
 
INQUIRIES
 
For further information, contact:
 
Dr. Alan Price or Ms. Carolyn Bowman
Office of Scientific Integrity
National Institutes of Health
Building 31, Room B1C39
Bethesda, MD  20892
Telephone:  (301) 496-2624
Fax:  (301) 402-0238
 
$$N2 END ************************************************************
 
$$N3 BEGIN **********************************************************
 
NCI BRIEFING ON "IMPLEMENTATION GRANTS FOR GENE THERAPY PROGRAMS IN
CANCER TREATMENT"
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
RFA:  CA-92-13
 
P.T. 34; K.W. 0715035, 0745032
 
National Cancer Institute
 
The notice of availability of a Request for Applications (RFA) for to
invite program project grant applications (P01) from interested
investigators to establish interactive Gene Therapy Programs with the
goal of conducting gene therapy clinical trials for cancer treatment
was published in the NIH Guide for Grants and Contracts, Vol. 21, No.
3, Part II of II, January 24, 1992.
 
The National Cancer Institute (NCI) will hold a briefing session
concerning this RFA on Friday, February 28, 1992 at the Holiday Inn
Crowne Plaza in Rockville, Maryland.  The briefing session will provide
information on the regulatory process for obtaining approval to conduct
gene therapy clinical trials .  The briefing will begin at 8:30 a.m.
and will adjourn by 4:00 p.m.  There will be ample time for questions
and answers.  A summary of the proceedings of this meeting including
questions and answers and copies of handouts, will be available upon
request to Diane Bronzert.
 
All interested parties are invited to attend.  Rooms for the night of
February 27 are available for a special rate of $89.00 plus tax.
Reservations must be made directly to the Holiday Inn Crowne Plaza at
(301) 468-1100. To receive the special rate, make the reservation by
February 14 and mention the NCI Gene Therapy Programs meeting.  For
further information and to register for the meeting, contact:
 
Diane Bronzert, Program Director
Cancer Therapy Evaluation Program
Division of Cancer Treatment
National Cancer Institute
Bethesda, MD  20892
Telephone:  (301) 496-8866
FAX:  (301) 480-4663
 
$$N3 END ************************************************************
 
$$N4 BEGIN **********************************************************
 
FUNDING STRATEGIES FOR FY 1992
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
P.T. 34; K.W. 1014006
 
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
 
The core principles described below will guide the  Institutes/
Centers/Divisions (ICDs) in making funding decisions on Research
Project Grants (RPGs) in FY 92.
 
Non-Competing RPGs
 
o  The award of non-competing grants at committed levels is the
cornerstone of the National Institutes of Health (NIH) and Alcohol,
Drug Abuse, and Mental Health Administration (ADAMHA) Financial
Management Plan and is the basis for credibility with the Congress and
the scientific community.
 
o  The total costs of the cohort of non-competing grants, on the
average, may not exceed 4 percent more than the prior budget period,
taking into account one-time, non-recurring costs such as equipment.
(ADAMHA noncompeting continuation awards will not come under this
policy until FY 93).
 
o  Every effort will be made to accommodate shifts in the fiscal
situation.  If conditions are such that funding at the committed levels
is not possible, the ICDs will obtain the approval of the Director,
NIH, or the Administrator, ADAMHA, before taking any action to reduce
the size of the non-competing awards.
 
Competing RPGs
 
o  The average costs of competing grants in one fiscal year will not
increase by more than the Biomedical Research and Development Price
Index over the average costs of competing grants in the previous fiscal
year (including Small Business Innovation Research grants).
 
o  In making funding decisions, ICDs should consider the total costs of
a grant, especially for applications a with percentiles at the margin
of the funding level.
 
o  An appropriate funding level for each award may be achieved by
making budgetary reductions based on recommendations of the initial
review group and advisory council/board, reviews by program and grants
management staff for cost allowability and reasonableness, and, if
necessary, programmatic adjustments.  Programmatic adjustments may
include reductions in investigator effort, adjustments of specific
budget items, and/or decreases in the number of specific aims.
 
o  Award reductions of 25 percent or more below the level recommended
by the initial review group on a single grant application may require
a revised statement of specific aims and a revised budget from the
Principal Investigator, properly countersigned by the institution,
which must be reviewed and approved by the ICD program and grants
management staff.  Program staff, in consultation with the Principal
Investigator and grants management staff, will decide if revised
specific aims are required.
 
o  For competing continuation grants, one factor in arriving at the
award amount will be the level of support in prior years and the extent
to which the ICD can permit growth within the existing constraints on
increases in average costs.
 
o  The average length of research project grants will not exceed four
years (excluding Small Business Innovation Research grants).
 
Indirect Costs
 
The NIH and ADAMHA Financial Management Plans propose that, the
effective indirect cost rate for competing and non-competing awards
would become the ceiling rate for the remainder of the recommended
period of support.  Implementation of the ceiling on the rate of
indirect costs is being deferred.  However, the Department of Health
and Human Services and the Office of Management and Budget, currently
are considering this and other options for government-vide policies
with respect to indirect costs.
 
This statement supersedes the previous informational footnotes on NIH
Notices of Grant Award regarding this subject.
 
$$N4 END ************************************************************
 
$$N5 BEGIN **********************************************************
 
NATIONAL WORKSHOPS ON THE PROTECTION OF HUMAN SUBJECTS
 
P.T. 42; K.W. 0783005
 
National Institutes of Health
Food and Drug Administration
 
The National Institutes of Health (NIH) and the Food and Drug
Administration (FDA) are sponsoring a series of workshops on the
responsibilities of researchers, Institutional Review Boards (IRBs),
and institutional officials for the protection of human subjects in
research.  The workshops are open to everyone with an interest in
research involving human subjects.  The meetings should be of special
interest to those persons currently serving or about to begin serving
as a member of an IRB.  Issues discussed at these workshops are
relevant to all other Public Health Service agencies.  The current
schedule includes the following:
 
SOUTH MIDWESTERN WORKSHOP
 
DATES:  February 20 and 21, 1992
 
WORKSHOP SITE:  San Antonio, TX
 
SPONSORS:
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, TX  78284-7972
 
St. Mary's University
One Camino Santa Maria
San Antonio, TX  78228-8572
 
REGISTRATION CONTACT:
Ms. Angie Khan
Institutional Coordinator of Research Review
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive (Room 402L)
San Antonio, TX  78284-7972
Telephone:  (512) 567-2351
 
TOPIC:  Identifying and Assessing Risks in Human Subject Research
 
SOUTHWEST WORKSHOP
 
DATES:  March 24, 25, and 26, 1992
 
WORKSHOP SITE:  Sheraton Old Town Hotel
                800 Rio Grande Blvd., N.W.
                Albuquerque, NM  87104
 
SPONSORS:  University of New Mexico
           Albuquerque, NM  87131-5126
 
           Navajo Community College
           Shiprock, NM  87420
 
REGISTRATION CONTACT:
University of New Mexico
Office of Continuing Medical Education
Health Sciences and Services Building (Room 140)
Box 713
Albuquerque, NM  87131-5126
Telephone:  (505) 277-3942
 
TOPIC:  Ethics, Justice, and Tribal Participation in Research with
American Indians
 
NOTE:  In conjunction with this Workshop, a session entitled, "Basic
Training for IRB Members," will be held from 1:00 p.m. on March 24
until noon on March 25.  During this session the Workshop participants
will be divided into four IRBs that will review four different research
protocols involving American Indians.  The full conference will convene
at 1:00 p.m. on March 25 and continue until 6:00 p.m. on March 26.
 
NORTHEASTERN WORKSHOP
 
DATES:  April 27 and 28, 1992
 
WORKSHOP SITE:  Philadelphia, PA
 
SPONSORS:
University of Pennsylvania
133 South 36th Street, Suite 300
Philadelphia, PA  19104-3246
 
Lincoln University
Lincoln University, PA  19352
 
REGISTRATION CONTACT:
Ms. Lynn Bevan
Assistant Director
Office of Research Administration
University of Pennsylvania
133 South 36th Street, Suite 300
Philadelphia, PA  19104-3246
Telephone:  (215) 898-2614
 
TOPIC:  The Shifting Ground:  Current Issues for the Protection of
Human Subjects on Biomedical and Behavioral Research
 
For further information regarding these workshops and future NIH/FDA
National Protection of Human Subjects Workshops, please contact:
 
Ms. Darlene Marie Ross
Executive Assistant for Education
Division of Human Subject Protections
Office for Protection from Research Risks
National Institutes of Health
9000 Rockville Pike
Building 31, Room 5B59
Bethesda, MD  20892
Telephone:  (301) 496-8101
 
$$N5 END ************************************************************
 
                     NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$R1 BEGIN NICHD-CD-92-09 *******************************************
 
SYNTHESIS AND TESTING OF MALE CONTRACEPTIVE AGENTS
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
RFP AVAILABLE:  NICHD-CD-92-09
 
P.T. 34; K.W. 1003006, 1002012, 0750020
 
National Institute of Child Health and Human Development
 
The Contraceptive Development Branch of the Center for Population
Research, National Institute of Child Health and Human Development, has
a requirement for the synthesis and testing of male contraceptive
agents.  The specific objectives of the project are the design,
synthesis, and testing of male contraceptive agents that inhibit
testicular sperm development, post-testicular sperm maturation, and
epididymal function.
 
Organizations must have adequate facilities and capabilities to carry
out the proposed synthetic chemical capabilities to carry out the
proposed synthetic chemical program.  Specifically excluded from this
project are LHRH analogs, gossypol derivatives, sex steroids, cytotoxic
agents, and all alkylating agents including chlorohydrin,
deoxyhalosugars, nitrogen mustards, ethyleneimines, and
sulfonoxyalkanes.  Non-specific antimetabolites, antimitotic agents, N-
Substituted diamines (such as WIN. 13,099), most major classes of
antibiotics, including the macrolides, aminoglycosides, penicillins,
tetracyclines, sulfasalazine, and co-trimoxazole, and nitroheterocyclic
compounds are also excluded.  Proposals to merely collect compounds
from various sources and/or only perform biological assays will not be
considered.
 
It is anticipated that four contract awards will be made for a maximum
period of three years each.
 
This announcement is not a Request for Proposals (RFP).  The RFP will
be issued on or about February 3, 1992.  Proposals will be due
approximately 90 days thereafter.  Requests for copies of the RFP may
be directed to:
 
Paul J. Duska, Contracting Officer
Contracts Management Branch, OGC
National Institute of Child Health and Human Development
Executive Plaza North, Room 610
900 Rockville Pike
Bethesda, MD  20892
FAX:  (301) 402-0915
 
$$R1 END ************************************************************
 
$$R2 BEGIN NIH-NINDS-92-14 ******************************************
 
MICROSTIMULATION OF THE SACRAL SPINAL CORD - MAPPING
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
RFP AVAILABLE:  NIH-NINDS-92-14
 
P.T. 34; K.W. 0745047, 0740050
 
National Institute of Neurological Disorders and Stroke
 
The Neural Prosthesis Program of the National Institute of Neurological
Disorders and Stroke, National Institutes of Health, is developing aids
for the neurologically handicapped.  These aids, known as neural
prostheses, replace or supplement neurological function by directly
interfacing with the nervous system.  One means of accomplishing this
is by microstimulation with microelectrodes implanted directly into
neural tissue.  Animal studies have shown the potential value of
microstimulation with respect to increased stimulus selectivity.  The
principal goal of the proposed project is to investigate the
feasibility of microstimulation of the sacral spinal cord as a method
of controlling micturition and other somatic and autonomic functions.
A research team with experience in neuroanatomical tracing,
electrophysiology, and genito-urinary physiology will be required to
successfully conduct this research.  It is anticipated that one award
will be made for a period of three years in September 1992.
 
This is not a Request for Proposals (RFP).  To receive a copy of the
RFP, submit a written request to the following address and supply two
self-addressed mailing labels.  All responsible sources shall be
considered by the agency.  The RFP will be issued on or about February
3, 1992, with proposals due on April 3, 1992.
 
Contracting Officer
Contracts Management Branch, DEA
National Institute of Neurological Disorders and Stroke
Federal Building, Room 901
7550 Wisconsin Avenue
Bethesda, MD  20892
 
Attention:  RFP No. NIH-NINDS-92-14
 
$$R2 END ************************************************************
 
$$R3 BEGIN NIH-NINDS-92-13 ******************************************
 
MICROMACHINED STIMULATING ELECTRODES
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
RFP AVAILABLE:  NIH-NINDS-92-13
 
P.T. 34; K.W. 0745047, 0706000
 
National Institute of Neurological Disorders and Stroke
 
The Neural Prosthesis Program of the National Institute of Neurological
Disorders and Stroke, National Institutes of Health, is seeking a
contract to design and fabricate arrays of multielectrode stimulating
probes capable of independently stimulating multiple small populations
of neurons within the central nervous system. This project will involve
research and development on micromachined, two and three dimensional
thin-film electrode arrays capable of independently stimulating
clusters of cells in the central nervous system.  These electrodes will
be designed to provide intracortical microstimulation at multiple sites
in the visual cortex. The techniques developed will also be applicable
to spinal cord microstimulating electrodes needed for future bladder
and motor prostheses.  It is anticipated that one award will be made
for a period of three years in September 1992.
 
This is not a Request for Proposals (RFP).  To receive a copy of the
RFP, submit a written request to the address indicated below and supply
two self-addressed mailing labels.  All responsible sources shall be
considered by the agency.  The RFP will be issued on or about January
24, 1992, with proposals due on or about March 23, 1992.
 
Contracting Officer
Contracts Management Branch, DEA
National Institute of Neurological Disorders and Stroke
Federal Building, Room 901
7550 Wisconsin Avenue
Bethesda, MD  20892
 
Attention:  RFP No. NIH-NINDS-92-13
 
$$R3 END ************************************************************
 
$$R4 BEGIN NHLBI-HC-92-03 *******************************************
 
TREATMENT OF RAYNAUD'S SYNDROME - CLINICAL UNITS
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
RFP AVAILABLE:  NHLBI-HC-92-03
 
P.T. 34; K.W. 0715040, 0755015, 0740013
 
National Heart, Lung, and Blood Institute
 
The National Heart, Lung, and Blood Institute (NHLBI) requires six
clinical units to conduct a randomized clinical trial of
pharmacological and non-pharmacological treatments for Raynaud's
syndrome.  The primary goals of the study are to determine the best
therapies for primary Raynaud's syndrome, particularly regarding the
efficacy and duration of benefit from a course of temperature
biofeedback treatment.  Additionally, the study will evaluate the
efficacy of the biofeedback approach in pre-sclerodermal Raynaud's and
establish new information with respect to the role of emotional
reactivity in the onset of symptoms.  The study population for the
Raynaud's Treatment Study will consist of approximately 480 patients
recruited from six participating clinical units.
 
The period of performance is anticipated to begin September 30, 1992
through March 31, 1996.
 
The Request for Proposals (RFP) NHLBI-HC-92-03 will be available on or
about January 28, 1992, with proposals due April 17, 1992.  Six awards
are anticipated to be made during September 1992.  Written requests for
the RFP must include three mailing labels, self-addressed, and must
cite RFP No. NHLBI-HC-92-03.
 
Requests for copies of the RFP are to be sent to:
 
William M. Stevens
Contract Specialist for ECA Contracts Section
National Heart, Lung, and Blood Institute
Federal Building, Room 3C16
Bethesda, MD  20892
 
$$R4 END ************************************************************
 
$$R5 BEGIN NHLBI-HC-92-10 *******************************************
 
CLINICAL TRIAL OF AN IMPLANTABLE CARDIAC DEFIBRILLATOR
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
RFP AVAILABLE:  NHLBI-HC-92-10
 
P.T. 34; K.W. 0740035, 0755015
 
National Heart, Lung, and Blood Institute
 
The National Heart, Lung, and Blood Institute (NHLBI) requires one
institution to conduct a multicenter trial to assess whether or not the
use of an implantable cardiac defibrillator will result in reduced
total mortality in comparison to conventional pharmacologic therapy in
patients who have been resuscitated from sudden cardiac death or are
otherwise at very high risk of mortality from arrhythmic causes.  The
study will consist of a pilot phase and a full-scale trial.  Two
hundred patients will be entered into the pilot study.  If the pilot
study demonstrates that a full-scale trial is feasible, approximately
1,000 patients will be entered into the full-scale study.
 
The period of performance is anticipated for 89 months beginning in
September 1992.
 
This is a notice of availability of a Request for Proposals (RFP).  RFP
NHLBI-HC-92-10 will be available on or about January 28, 1992, with
proposals due April 4, 1992.  One award is anticipated by the
Government.  Only North American offeror institutions will be
considered.  Written requests for the RFP must include three mailing
labels, self-addressed, and must cite RFP NHLBI-HC-92-10.
 
Requests for copies of the RFP are to be sent to:
 
Cheryl A. Jennings
Contracting Officer for ECA Contracts Section
National Heart, Lung, and Blood Institute
Federal Building, Room 3C16
Bethesda, MD  20892
 
$$R5 END ************************************************************
 
$$R6 BEGIN OD-92-02 FULL-TEXT ***************************************
 
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTION PROJECTS
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
RFA AVAILABLE:  OD-92-02
 
P.T. 02; K.W. 0715008, 0715035, 0715040, 1002046, 0735000
 
National Institutes of Health
 
Letter of Intent Receipt Date:  March 10, 1992
Application Receipt Date:  April 27, 1992
 
The Request for Applications (RFA) announced in this notice contains
essential information for the preparation of an application.  Potential
applications may obtain the RFA from the contact named in INQUIRIES,
below.
 
PURPOSE
 
Public Law Number 102-170, the Appropriations Act for the Department of
Health and Human Services for Fiscal Year 1992, provides $7,500,000 in
the budget of the Office of the Director, National Institutes of Health
(NIH) for extramural facilities construction grants, to be awarded
competitively.  The NIH announces the availability of an RFA for the
construction of facilities of urgent National importance for biomedical
research and/or services to support such research.
 
The main objective of this construction program is to facilitate the
conduct of biomedical research by providing funds for construction of
new facilities and for the purchase of associated fixed research
equipment essential for the operation of these facilities.  Support may
be requested for the construction of new facilities and additions or
renovations to existing facilities to meet the biomedical research
and/or biomedical research support needs of an institution or of a
research group at that institution or elsewhere that utilizes the
resources of that institution.  The purpose of the proposed facility
must be within the scope of one of the statutes authorizing the awards.
Those statutes authorize construction grants that would benefit the
fields of cancer, vision, heart, lung, blood, and AIDS research.
 
ELIGIBILITY REQUIREMENTS
 
Domestic, non-Federal, public and private non- profit institutions,
organizations, and associations that conduct or support biomedical
research are eligible to apply.
 
MECHANISM OF SUPPORT
 
The award mechanism will be the construction grant award (C06).  Awards
will be administered under Federal Regulation 45 CFR Part 74 -
Administration of Grants, and for cancer construction projects, 42 CFR
Part 52b.
 
FUNDS AVAILABLE
 
This one-time solicitation based on the Fiscal Year 1992 appropriation
provides $7,500,000 for this initiative.  It is anticipated that four
to five awards will be made.  Up to 50 percent of the allowable costs
of a project may be awarded, not to exceed $2,000,000.  Prior to grant
award, the applicant must provide an assurance of required matching
funds and that additional funds will be secured to meet any projected
costs in excess of the award amount.  Requests of less than $500,000
will not be accepted.  No indirect costs or continuation costs will be
awarded.
 
LETTER OF INTENT
 
Prospective applicants are asked to submit by March 10, 1992, a letter
of intent to the individual noted below.  The letter, requested for
planning purposes only, is to include the RFA number noted above, the
name of the Principal Investigator, and a brief title of the type(s) of
research/research support to be conducted in the new facility.  The
letter of intent does not commit the sender to submit an application,
nor is it a prerequisite for submission of an application.  The letter
of intent is to be addressed to:
 
Mr. Kenneth Brow
Chief, Research Facilities Branch
Division of Cancer Biology, Diagnosis, and Centers
National Cancer Institute
Executive Plaza North, Room 300
Bethesda, MD  20892
Telephone:  (301) 496-8534
 
APPLICATION PROCEDURES
 
Applicants must use Standard Form 424, "Application for Federal
Assistance." Application forms and special instructions for completing
the forms relevant to this RFA must be requested from the staff contact
official noted below.
 
REVIEW CONSIDERATIONS
 
Applications that are complete and responsive will be reviewed for
scientific and technical merit by appropriate special peer review
group(s) that will be convened by the Division of Research Grants, NIH.
The second level of peer review will be conducted by the National
Advisory Board or Council appropriate for the statutory authority that
is applicable to the application.  Detailed criteria on which the
applications will be evaluated are discussed in detail in the RFA.
 
INQUIRIES
 
For additional information, a copy of the RFA and application Standard
Form 424 materials, contact:
 
Mr. Kenneth Brow
Chief, Research Facilities Branch
Division of Cancer Biology, Diagnosis, and Centers
National Cancer Institute
Executive Plaza North, Room 300
Bethesda, MD  20892
Telephone:  (301) 496-8534
 
The programmatic and fiscal contacts are listed in the RFA.
 
AUTHORITY AND REGULATIONS
 
Grants for research facilities construction programs of the National
Institutes of Health are subject to Executive Order 12372.  Awards will
be made under the construction grants authorities in the Public Health
Service Act, Title IV, Sections 413(b)(6)(B), 421(b)(2)(B), 455, and
2351(a)(7)(B) and administered under PHS grants policies and Federal
Regulations 45 CFR Part 74 and 42 CFR Part 52b for cancer construction
only.  This program is described in the Catalog of Federal Domestic
Assistance, Number 93.392, Cancer-Construction.
 
$$R6 END ************************************************************
 
$$R7 BEGIN HD-92-08 FULL-TEXT ***************************************
 
ORTHOTICS AND PROSTHETICS RESEARCH
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
RFA AVAILABLE:  HD-92-08
 
P.T. 34; K.W. 0415003, 0740070, 0710020, 1004015, 0710030
 
National Institute of Child Health and Human Development (NICHD)
 
Application Receipt Date:  May 26, 1992
 
THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.
 
PURPOSE
 
The National Center for Medical Rehabilitation Research (NCMRR) of the
National Institute of Child Health and Human Development (NICHD)
invites research grant applications (R01) to develop new knowledge in
the area of orthotic devices and internal and external prosthetic
devices.  Basic, clinical, and applied research applications that
examine the development and improvement of orthotic and prosthetic
devices are of high priority.  Interdisciplinary, collaborative
projects between specialists in physical and rehabilitation medicine
(physiatry), basic and social scientists, and biomedical engineering
are encouraged to apply improved understanding of human functioning and
behavior to development and improvement of rehabilitation devices.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention goals of "Healthy People 2000," a
PHS-led national activity for setting priorities.  This RFA, Orthotics
and Prosthetics Research, is related to the priority areas of
nutrition, physical activity and fitness, heart disease and stroke,
cancer, and diabetes and chronic disabling conditions.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
No. 017-001-474-0, or Summary Report:  Stock No 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (Telephone:  202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Applications may be submitted by public and private non-profit and for-
profit organizations such as universities, colleges, hospitals,
laboratories, units of State and local governments, and eligible
agencies of the Federal Government.  Women and minority investigators
are encouraged to apply.
 
MECHANISM OF SUPPORT
 
This RFA will use the National Institutes of Health (NIH) individual
research grant (R01).  Responsibility for the planning, direction, and
execution of the proposed project will be solely that of the applicant.
Project support may be requested for one to five years and may be
renewed according to the conventional procedures that pertain to PHS
grants.  The earliest anticipated award date will be September 1992.
 
This RFA is a one-time solicitation.  Future unsolicited competing
continuation applications will compete with all investigator-initiated
applications and be reviewed according to the customary NIH peer review
procedures.
 
FUNDS AVAILABLE
 
Applications submitted in response to this announcement will compete
for approximately $1,000,000 in grant money that has been made
available for this purpose in Fiscal Year 1992.  This is a one-time
announcement.  The NICHD expects to award approximately five to seven
grants.  The number of awards depends upon the scientific merit of the
applications, the degree of relevance to the stated goal of the
announcement and the availability of funds.
 
RESEARCH OBJECTIVES
 
This RFA invites scientists to submit grant applications for research
on the development and improvement of prosthetics and orthotics.
Research in the areas of biomechanics, ergonomics, and engineering
design has been impeded by gaps in knowledge.  Applicants must propose
investigations that employ interdisciplinary tactics for conducting
research with the goals of maximizing function, comfort and support,
minimal weight, cost effectiveness, and the highest degree of
replication of natural function possible.  Specific topics cited below
are examples and should not be considered exhaustive of the potential
types of research questions on orthotics and prosthetics that could be
supported under this RFA.
 
o  Biomaterials - development of new composite materials for
prosthetics and orthotics
 
o  Energy consumption and prosthetic use - physiological costs of
ambulation
 
o  Gait changes with different prosthetic devices - optimal mobility
using device
 
o  Prosthetic and orthotic device design development for different
functions - new functions for different settings
 
o  Biomechanics of prosthetic attachment to limbs - simulation of
normal motion
 
o  Tissue properties under physiological loads - in situ evaluation of
tissue properties
 
o  Methods of powering prosthetic devices - myoelectric, mechanically
powered devices
 
o  Computers in the design and manufacture of prosthetic devices -
dynamic CAD
 
o  Sensory feedback systems which are adaptable to prosthetic and
orthotic devices - improvement in tactile, proprioceptive, and pressure
sense
 
o  Impact of surgery as related to orthotics and prosthetics
 
o  Effects of long-term use of orthotics and prosthetics
 
STUDY POPULATIONS
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a special justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.
 
APPLICATION PROCEDURES
 
Applicants are to use form PHS 398 (rev. 9/91).  This application form
is available in the business or grants and contracts office at most
academic and research institutions and from the Office of Grants
Inquires, Division of Research Grants, National Institutes of Health,
Westwood Building, Room 449, Bethesda, MD 20892, telephone (301)
496-7441.  The receipt deadline for applications prepared in response
to this RFA is May 26, 1992.  Late applications will be returned to the
applicant without review.
 
REVIEW CONSIDERATIONS
 
Applications will be reviewed by NICHD staff for responsiveness to the
RFA.  Applications deemed non-responsive will be returned to the
applicant.  In the event that an application is returned, the applicant
has the option to resubmit the application to the Division of Research
Grants as an unsolicited application during one of the three yearly
review cycles (February 1, June 1, and October 1).  If the application
submitted in response to this RFA is substantially similar to a grant
application already submitted to the NIH for review, but has not yet
been reviewed, the applicant will asked to withdraw either the pending
application or the new one.  Simultaneous submission of identical
applications will not be allowed, nor will essentially identical
applications be reviewed by different review committees.  Therefore, an
application cannot be submitted in response to this RFA that is
essentially identical to one that has already been reviewed.  This does
not preclude the submission of the substantial revisions of
applications already reviewed, but such applications must include an
introduction addressing the previous critique.
 
Responsive applications may be evaluated by preliminary triage in a
peer review group to determine scientific merit relative to other
applications received in response to this RFA.  Those applications
judged to be non-competitive will be withdrawn and the applicant and
the institutional business official will be notified. Those
applications judged to be competitive will be further evaluated for
technical and scientific merit by a review panel convened for this
purpose by the Division of Scientific Review, NICHD.
 
Review criteria will be those used by the PHS to evaluate investigator-
initiated R01 applications.
 
Following the initial review by study section, applications will be
reviewed by the NICHD National Advisory Council.
 
INQUIRIES
 
Written and telephone requests for the RFA may be addressed to:
 
Louis A. Quatrano, Ph.D.
Chief, Applied Rehabilitation Medicine Research Branch
National Center for Medical Rehabilitation Research
National Institute of Child Health and Human Development
Executive Plaza South, Room 450W
6120 Executive Boulevard
Rockville, MD  20852
Telephone:  301) 402-2242
 
For fiscal and administrative inquires regarding this announcement,
potential applicants may write or call:
 
E. Douglas Shawver
Office of Grants and Contracts
National Institute of Child Health and Human Development
Executive Plaza North, Room 501
6130 Executive Boulevard
Rockville, MD  20892
Telephone:  (301) 496-1303

AUTHORITY AND REGULATION
 
This program is described in the Catalog of Federal Domestic Assistance
No. 93.929-Medical Rehabilitation Research.  Awards are under
authorization of the Public Health Service Act, Title IV, Part A
(Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and
285) and administered under PHS grants policies and Federal Regulations
42 CFR 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.
 
$$R7 END ************************************************************
 
                                     ERRATUM
 
$$E1 BEGIN R2 19920117 APPEND RFA NIAID-DAIDS-92-15 BOTH ***************
 
EVALUATION OF IMMUNE-BASED THERAPIES FOR AIDS USING ANIMAL MODELS
 
NIH GUIDE, Volume 21, Number 4, January 31, 1992
 
RFP AVAILABLE:  NIH-NIAID-DAIDS-92-15
 
P.T. 34; K.W. 0745045, 0715008, 0755020
 
National Institute of Allergy and Infectious Diseases
 
The notice of availability of this Request for Proposals (RFP) was
published in the NIH Guide for Grants and Contracts on January 17,
1992, Vol. 21, No. 2.  This requirement has been amended to DELETE Part
B entitled: Evaluation of Multipotent Stem Cell Reconstitution as a
Therapy to Restore Immune Cell Deficits, and now consists only of:
Evaluation of Immune-Based Therapies for AIDS Using Animal Models.
This will provide for the evaluation of immune-based therapies in an
established small animal model.
 
Requests for the RFP shall be directed in writing to:
 
Cyndie Cotter
Contract Management Branch
National Institute of Allergy and Infectious Diseases
Solar Building, Room 3C-07,
6003 Executive Boulevard
Bethesda, MD  20892
 
To receive a copy of the RFP, supply this office with two
self-addressed labels.
 
All responsible sources may submit a proposal that will be considered.
 
This announcement does not commit the Government to award a contract.
 
$$E1 END ************************************************************